Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

6.0K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
6.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.0K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

6.3K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

10.9K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.9K
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

7.4K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of intraoperative dexamethasone on glycaemic responses in people with diabetes mellitus: a preplanned analysis of the Perioperative ADministration of Dexamethasone and Infection trial.

British journal of anaesthesia·2026
Same author

Symptomatic hypocalcaemia after administration of denosumab and iron infusion in patients with normal and impaired renal function.

Internal medicine journal·2025
Same author

Incidence, prevalence, and predictors of osteoporotic fracture in adult lung transplant recipients.

JHLT open·2025
Same author

The Utility of Magnetic Resonance Imaging for Hypophysitis Secondary to Immune Checkpoint Inhibitor Use.

Clinical endocrinology·2025
Same author

Six months of hybrid closed-loop therapy improves diabetes-specific positive well-being, and reduces diabetes distress and fear of hypoglycemia: secondary analysis of a randomized controlled trial.

BMJ open diabetes research & care·2025
Same author

Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes.

Internal medicine journal·2024

Related Experiment Video

Updated: Mar 30, 2026

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay
08:34

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay

Published on: July 15, 2025

764

Insulin-like growth factor binding proteins 4-6.

Leon A Bach1

  • 1Department of Medicine (Alfred), Monash University, Prahran, 3181, Australia; Department of Endocrinology and Diabetes, Alfred Hospital, Melbourne, 3004, Australia.

Best Practice & Research. Clinical Endocrinology & Metabolism
|November 3, 2015
PubMed
Summary

Insulin-like growth factor binding proteins (IGFBPs) 4-6 modulate insulin-like growth factor (IGF) actions, with distinct inhibitory or enhancing roles. While implicated in diseases like cancer, their serum levels lack current clinical utility.

Keywords:
binding proteincellular actioninsulin-like growth factorprotein structureregulation

More Related Videos

Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells
06:33

Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells

Published on: February 2, 2024

2.8K
Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer
08:20

Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer

Published on: May 21, 2019

6.1K

Related Experiment Videos

Last Updated: Mar 30, 2026

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay
08:34

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay

Published on: July 15, 2025

764
Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells
06:33

Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells

Published on: February 2, 2024

2.8K
Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer
08:20

Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer

Published on: May 21, 2019

6.1K

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Cell Biology

Background:

  • Insulin-like growth factor binding proteins (IGFBPs) 4-6 are key regulators of insulin-like growth factor (IGF) signaling pathways.
  • IGFBP-4 and IGFBP-6 primarily inhibit IGF actions, while IGFBP-5 exhibits context-dependent enhancement.
  • IGFBP-6 displays a specific preference for binding IGF-II.

Purpose of the Study:

  • To elucidate the distinct roles and binding characteristics of IGFBPs 4-6 in modulating IGF actions.
  • To explore the formation of IGFBP-IGF complexes and their implications for IGF bioavailability.
  • To investigate the IGF-independent functions and disease relevance of IGFBPs 4-6.

Main Methods:

  • Analysis of IGFBP-IGF interactions and complex formation (binary and ternary).
  • Examination of IGF-independent actions of IGFBPs 4-6.
  • Review of cellular regulation and disease associations of IGFBPs 4-6.

Main Results:

  • IGFBP-4 and IGFBP-6 predominantly inhibit IGF activity, whereas IGFBP-5 can enhance it.
  • Circulating IGFBPs 4-6 form complexes with IGFs, influencing tissue entry and bioavailability.
  • IGFBP-5 forms ternary complexes, creating an IGF reservoir within the circulation.
  • IGFBP-4, -5, and -6 possess IGF-independent functions and are regulated in a cell-specific manner.

Conclusions:

  • IGFBP-4, -5, and -6 are crucial modulators of IGF signaling with diverse functions.
  • Dysregulation of these IGFBPs is linked to various diseases, including cancer.
  • Currently, there is no established clinical indication for measuring serum levels of IGFBPs 4-6.